PMID- 30577083
OWN - NLM
STAT- MEDLINE
DCOM- 20190327
LR  - 20220830
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 12
IP  - 12
DP  - 2018 Dec 22
TI  - Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use 
      disorders.
PG  - CD011315
LID - 10.1002/14651858.CD011315.pub2 [doi]
LID - CD011315
AB  - BACKGROUND: Amphetamine-type stimulants (ATS) refer to a group of synthetic 
      stimulants including amphetamine, methamphetamine, 
      3,4-methylenedioxy-methamphetamine (MDMA) and related substances. ATS are highly 
      addictive and prolonged use may result in a series of mental and physical 
      symptoms including anxiety, confusion, insomnia, mood disturbances, cognitive 
      impairments, paranoia, hallucinations and delusion.Currently there is no widely 
      accepted treatment for ATS-use disorder. However, cognitive-behavioural treatment 
      (CBT) is the first-choice treatment. The effectiveness of CBT for other 
      substance-use disorders (e.g. alcohol-, opioid- and cocaine-use disorders) has 
      been well documented and as such this basic treatment approach has been applied 
      to the ATS-use disorder. OBJECTIVES: To investigate the efficacy of 
      cognitive-behavioural treatment for people with ATS-use disorder for reducing ATS 
      use compared to other types of psychotherapy, pharmacotherapy, 12-step 
      facilitation, no intervention or treatment as usual. SEARCH METHODS: We 
      identified randomised controlled trials (RCT) and quasi-RCTs comparing CBT for 
      ATS-use disorders with other types of psychotherapy, pharmacotherapy, 12 step 
      facilitation or no intervention. We searched the Cochrane Drugs and Alcohol Group 
      Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE via 
      PubMed, Embase and five other databases up to July 2018. In addition, we examined 
      reference lists of eligible studies and other systematic reviews. We contacted 
      experts in the field. SELECTION CRITERIA: Eligibility criteria consisted of RCTs 
      and quasi-RCTs comparing CBT versus other types of interventions with adult ATS 
      users (aged 18 years or older) diagnosed by any explicit diagnostic system. 
      Primary outcomes included abstinence rate and other indicators of drug-using 
      behaviours. DATA COLLECTION AND ANALYSIS: We used standard methodological 
      procedures expected by Cochrane. MAIN RESULTS: Only two studies met the 
      eligibility criteria. Both studies were at low risk of selection bias and 
      reporting bias. In one study, almost half of participants in the intervention 
      group dropped out and this study was at high risk of attrition bias. The studies 
      compared a single session of brief CBT or a web-based CBT to a waiting-list 
      control (total sample size across studies of 129). Results were mixed across the 
      studies. For the single-session brief CBT study, two out of five measures of drug 
      use produced significant results, percentage of abstinent days in 90 days (odds 
      ratio (OR) 0.22, 95% confidence interval (CI) 0.02 to 2.11) and dependence 
      symptoms (standardised mean difference (SMD) -0.59, 95% CI -1.16 to -0.02). 
      Little confidence could be placed in the results from this study give the small 
      sample size (25 participants per group) and corresponding large CIs around the 
      observed effects. For the web-based CBT, there was no significant difference 
      across different outcomes. Neither study reported adverse effects. The 
      meta-analytic mean across these two trials for drug use was not significant (SMD 
      -0.28, 95% CI -0.69 to 0.14). In summary, overall quality of evidence was low and 
      there was insufficient evidence to conclude that CBT is effective, or 
      ineffective, at treating ATS use. AUTHORS' CONCLUSIONS: Currently, there is not 
      enough evidence to establish the efficacy of CBT for ATS-use disorders because of 
      a paucity of high-quality research in this area.
FAU - Harada, Takayuki
AU  - Harada T
AD  - Department of Psychology, Mejiro University, 4-31-1 Naka-Ochiai, Shinjuku-ku, 
      Tokyo, Japan, 161-8539.
FAU - Tsutomi, Hiroshi
AU  - Tsutomi H
FAU - Mori, Rintaro
AU  - Mori R
FAU - Wilson, David B
AU  - Wilson DB
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20181222
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Amphetamines)
SB  - IM
UOF - doi: 10.1002/14651858.CD011315
MH  - Adult
MH  - Amphetamine-Related Disorders/complications/*therapy
MH  - *Amphetamines/adverse effects
MH  - Cognitive Behavioral Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Patient Dropouts/statistics & numerical data
MH  - Randomized Controlled Trials as Topic
MH  - Sample Size
MH  - Waiting Lists
PMC - PMC6516990
COIS- TH: none known. HT: none known. RM: none known. DW: none known.
EDAT- 2018/12/24 06:00
MHDA- 2019/03/28 06:00
PMCR- 2019/12/22
CRDT- 2018/12/22 06:00
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2019/03/28 06:00 [medline]
PHST- 2018/12/22 06:00 [entrez]
PHST- 2019/12/22 00:00 [pmc-release]
AID - CD011315.pub2 [pii]
AID - 10.1002/14651858.CD011315.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2018 Dec 22;12(12):CD011315. doi: 
      10.1002/14651858.CD011315.pub2.